ReviewCells2020
Urine as a Main Effector in Urological Tissue Engineering-A Double-Edged Sword.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Comment on "Single-staged in vivo co-transplantation of autologous muscular and urothelial micrografts as a composite tissue tube for urogenital reconstruction".Pediatric surgery international · 2026Article
- Urine-derived stem cells efficiently assemble into micro-bone organoids supported by decellularized bone matrix microparticles for rapidly repairing bone defects through direct filling and paracrine functions.Materials today. Bio · 2025Article
- Exosomes from CD133Journal of translational medicine · 2025Article
- Establishing an induced pluripotent stem cell bank using urine cells from pediatric patients with neurogenetic diseases.Clinical and experimental pediatrics · 2025Article
- KRT5Stem cell research & therapy · 2025Article
- Ureter reconstruction using a biotube in a canine model: A pilot stud.Journal of stem cells & regenerative medicine · 2025Article
- Application prospects of urine-derived stem cells in neurological and musculoskeletal diseases.World journal of orthopedics · 2024Review
- Review
- Urine-derived stem cells: Promising advancements and applications in regenerative medicine and beyond.Heliyon · 2024Review
- Autologous non-invasively derived stem cells mitochondria transfer shows therapeutic advantages in human embryo quality rescue.Biological research · 2023Article
- Skeletal Muscle-Derived Exosomal miR-146a-5p Inhibits Adipogenesis by Mediating Muscle-Fat Axis and Targeting GDF5-PPARγ Signaling.International journal of molecular sciences · 2023Article
- Polymeric Materials, Advances and Applications in Tissue Engineering: A Review.Bioengineering (Basel, Switzerland) · 2023Review
- Sources, Selection, and Microenvironmental Preconditioning of Cells for Urethral Tissue Engineering.International journal of molecular sciences · 2022Review
- Prospects and Challenges of Electrospun Cell and Drug Delivery Vehicles to Correct Urethral Stricture.International journal of molecular sciences · 2022Review
- Ultrasonographic Evaluation of the Hypospadiac Penis in Children.Frontiers in pediatrics · 2022Article
- Combination of PD98059 and TGF-β1 Efficiently Differentiates Human Urine-Derived Stem Cells into Smooth Muscle Cells.International journal of molecular sciences · 2021Article
- Urothelial Calcium-Sensing Receptor Modulates Micturition Function via Mediating Detrusor Activity and Ameliorates Bladder Hyperactivity in Rats.Pharmaceuticals (Basel, Switzerland) · 2021Article
- A Comprehensive Review of the Therapeutic Value of Urine-Derived Stem Cells.Frontiers in genetics · 2021Review
- The Plate Objective Scoring Tool (POST): Further Reflections and Extended Applications.Research and reports in urology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to reconstruct injured urinary tract tissues, biodegradable scaffolds with autologous seeded cells are explored in this work. However, when cells are obtained via biopsy from individuals who have damaged organs due to infection, congenital disorders, or cancer, this can result in unhealthy engineered cells and donor site morbidity. Thus, neo-organ construction through an alternative cell source might be useful. Significant advancements in the isolation and utilization of urine-derived stem cells have provided opportunities for this less invasive, limitless, and versatile source of cells to be employed in urologic tissue-engineered replacement. These cells have a high potential to differentiate into urothelial and smooth muscle cells. However, urinary tract reconstruction via tissue engineering is peculiar as it takes place in a milieu of urine that imposes certain risks on the implanted cells and scaffolds as a result of the highly cytotoxic nature of urine and its detrimental effect on both growth and differentiation of these cells. Both of these projections should be tackled thoughtfully when designing a suitable approach for repairing urinary tract defects and applying the needful precautions is vital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.